Urine i-TXB2 in renal allograft rejection

Area of Science:

• Nephrology
• Immunology
• Biomarker Discovery

Background:

• Renal allograft rejection poses a significant threat to long-term transplant survival.
• Early detection of rejection is crucial for timely intervention and improved patient outcomes.
• Current biomarkers for rejection lack sufficient sensitivity or specificity for early diagnosis.

Purpose of the Study:

• To investigate the potential of urinary immunoreactive thromboxane B2 (i-TXB2) as an early diagnostic marker for clinical renal allograft rejection.
• To compare the kinetics of i-TXB2 changes with established biomarkers like serum beta 2-microglobulin (beta 2-MG) and serum creatinine during rejection episodes.

Main Methods:

• Daily urine samples were collected from twelve kidney transplant recipients.
• Urinary i-TXB2 levels were measured and compared with serum beta 2-MG and serum creatinine.
• Levels were also monitored in patients with other conditions like deep venous thrombosis, urinary tract infection, pneumonia, and acute tubular necrosis.

Main Results:

• An increase in urinary i-TXB2 preceded the rise in serum beta 2-MG and clinical rejection diagnosis in 21 out of 30 rejection episodes.
• Elevated urinary i-TXB2 was observed before increased serum creatinine in 26 out of 30 rejection episodes.
• The magnitude of i-TXB2 change was greater than that of serum beta 2-MG or creatinine; i-TXB2 was not elevated in non-rejection conditions.

Conclusions:

• Urinary i-TXB2 emerges as a sensitive and early indicator of renal allograft rejection.
• This biomarker demonstrates potential for non-invasive monitoring of kidney transplant recipients.
• Further research is warranted to validate i-TXB2 as a routine clinical tool for transplant management.